Roche Holding AG’s Genentech lost an appeals court bid to halt Amgen Inc. from selling its Kanjinti breast cancer drug, a biosimilar of Genentech’s Herceptin, while an appeal is pending.
The U.S. Court of Appeals for the Federal Circuit said Genentech hadn’t established that such an order was warranted at this time, though its decision shouldn’t be seen as siding with either company on the ultimate disposition of the case. The court said arguments on the case will be held on the next available hearing date after legal papers are filed in the dispute.
©2019 Bloomberg L.P. All rights reserved. ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.